Fractional CO₂ laser therapy: a new challenge for vulvovaginal atrophy in postmenopausal women

References

• Portman DJ, Gass ML. Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society. Climacteric 2014;17:557–63
   PubMed Web of Science ®Google Scholar
• Archer DF. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 2010;17:194–203
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Pines A, Panay N, et al. International Menopause Society. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013;16:316–37
   PubMed Web of Science ®Google Scholar
• Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 2014;17:3–9
   PubMed Web of Science ®Google Scholar
• Suckling J, Kennedy R, Lethaby A, Roberts H. Local estrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006;(4):CD001500.
   PubMedGoogle Scholar
• Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009;6:2133–42
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey. Climacteric 2012;15:36–44
   PubMed Web of Science ®Google Scholar
• Simon JA, Nappi RE, Kingsberg SA, Maamari R, Brown V. Clarifying Vaginal Atrophy’s Impact on Sex and Relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partners. Menopause 2013;21:137–42
   Web of Science ®Google Scholar
• Nappi RE, Albani FE, Santamaria V, et al. Hormonal and psycho-relational aspects of sexual function during menopausal transition and at early menopause. Maturitas 2010;67:78–83
   PubMed Web of Science ®Google Scholar
• The North American Menopause Society (NAMS). Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20:888–902
   PubMed Web of Science ®Google Scholar
• The North American Menopause Society (NAMS). The 2012 Hormone Therapy Position Statement of the North American Menopause Society. Menopause 2012;19:257–71
   PubMed Web of Science ®Google Scholar
• Biglia N, Peano E, Sgandurra P, et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol 2010;26:404–12
   PubMed Web of Science ®Google Scholar
• Wills S, Ravipati A, Venuturumilli P, et al. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract 2012;8:144–8
   PubMedGoogle Scholar
• Donders G, Neven P, Moegele M, et al. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat 2014;145:371–9
   PubMed Web of Science ®Google Scholar
• Santen RJ, Pinkerton JV, Conaway M, et al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause 2002;9:179–87
   PubMed Web of Science ®Google Scholar
• Bachmann G, Lobo RA, Gut R, et al. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol 2008;111:67–76
   PubMed Web of Science ®Google Scholar
• Eugster-Mausmann M, Waitzinger W, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. Climacteric 2010;13:219–27
   PubMed Web of Science ®Google Scholar
• Delgado JL, Estevez J, Radicioni M, et al. Pharmacokinetics and preliminary efficacy of two vaginal gel formulations of ultra-low-dose estriol in postmenopausal women. Climacteric 2016;19:172–80
   PubMed Web of Science ®Google Scholar
• Cano A, Estévez J, Usandizaga R, et al. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study. Menopause 2012;19:1130–9
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Committee Opinion No. 659. Obstet Gynecol 2016;127:e93–6
   PubMed Web of Science ®Google Scholar
• Salvatore S, Leone Roberti Maggiore U, Athanasiou S, et al. Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study. Menopause 2015;22:845–9
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Levancini M, Cervigni M. Vaginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause. Climacteric 2015;18:157–63
   PubMed Web of Science ®Google Scholar
• Panay N. Genitourinary syndrome of the menopause–dawn of a new era? Climacteric 2015;18:13–17
   PubMed Web of Science ®Google Scholar
• Tierney EP, Hanke CW. Fractionated carbon dioxide laser treatment of photoaging: prospective study in 45 patients and review of the literature. Dermatol Surg 2011;37:1279–90
   PubMed Web of Science ®Google Scholar
• Huang AJ, Gregorich SE, Kuppermann M, et al. Day-to-Day Impact of Vaginal Aging questionnaire: a multidimensional measure of the impact of vaginal symptoms on functioning and well-being in postmenopausal women. Menopause 2014;22:144–54
   Web of Science ®Google Scholar
• Salvatore S, Nappi RE, Zerbinati N, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric 2014;17:363–9
   PubMed Web of Science ®Google Scholar
• Salvatore S, Nappi RE, Parma M, et al. Sexual function after fractional microablative CO2 laser in women with vulvovaginal atrophy. Climacteric 2015;18:219–25
   PubMed Web of Science ®Google Scholar
• Perino A, Calligaro A, Forlani F, et al. Vulvo-vaginal atrophy: a new treatment modality using thermo-ablative fractional CO2 laser. Maturitas 2015;80:296–301
   PubMed Web of Science ®Google Scholar
• Pagano T, De Rosa P, Vallone R, et al. Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer. a retrospective study. Menopause 2016;23:1108–13
   PubMed Web of Science ®Google Scholar
• Pieralli A, Fallani MG, Becorpi A, et al. Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors. Arch Gynecol Obstet 2016;294:841–6
   PubMed Web of Science ®Google Scholar